ResMed Inc. (RMD) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diag...
ResMed Inc.'s revenue increased 21.9% year over year, from $4.22B to $5.15B.
Net income increased 56.1% over the same period, from $897.6M to $1.40B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 180% in total.
Total debt decreased by 53.6% to $668.3M.
The debt-to-equity ratio stands at 0.11, indicating a conservative leverage profile.
Operating cash flow grew 152.6% to $1.75B.
ResMed Inc. maintains a strong net profit margin of 27.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $2.27B+105.5% | $428.2M | $1.25B | $564.1M | $559.1M | $6.91B | $1.23B | $4.48B |
| Q3 FY2024 | $3.46B+52.8% | $728.7M | $1.94B | $938.7M | $961.1M | $6.81B | $1.01B | $4.63B |
| Q1 FY2025 | $1.22B-64.6% | $311.4M | $717.2M | $387.3M | $325.5M | $7.22B | $677.5M | $5.20B |
| Q2 FY2025 | $2.51B+104.7% | $656.0M | $1.47B | $804.6M | $634.2M | $7.14B | $672.8M | $5.25B |
| Q3 FY2025 | $3.80B+51.5% | $1.02B | $2.23B | $1.23B | $1.21B | $7.57B | $673.0M | $5.55B |
| Q1 FY2026 | $1.34B-64.8% | $348.5M | $820.8M | $446.5M | $457.3M | $8.31B | $668.6M | $6.12B |
| Q2 FY2026 | $2.76B+106.5% | $741.1M | $1.70B | $938.2M | $797.1M | $8.50B | $663.8M | $6.32B |
| Q3 FY2026 | $4.19B+51.9% | $1.14B | $2.59B | $1.44B | $1.35B | $8.78B | $664.1M | $6.49B |
Balance Sheet Summary (Latest Period)
Total Assets
$8.17B
Total Liabilities
$2.21B
Total Equity
$5.97B
Cash & Equivalents
$1.21B
Total Debt
$668.3M
Current Assets
$3.51B
Current Liabilities
$1.02B
Retained Earnings
$6.08B